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Introduction
Integrase inhibitor raltegravir is being used increasingly
in patients with potential drug interactions [1]. We
describe a case of DRESS syndrome in a patient who
was switched to raltegravir from a PI based regime.
Case report
A 55 yr old patient was diagnosed with HIV in 2005 with
a nadir CD4 30. Virological suppression was achieved on
NNRTI based HAART. Following the development of
resistance this was later switched to a PI based regime
with a good virological response. In order to treat her
severe post herpetic neuralgia secondary to multi derma-
tome herpes zoster, she was given epidural corticosteroid,
triamcinolone. Forty one days later she presented with
Cushing’s syndrome. This was due to the interaction of
corticosteroid with PI.
The PI was changed to raltegravir to avoid further
interactions; the patient maintained viral suppression.
Four weeks after commencing raltegravir she presented
with a 2-day history of a rapidly progressive generalized
maculopapular rash, pruritis, malaise and pyrexia. Eosi-
nophil count was 1.5x10
9/l. A clinical diagnosis of
DRESS syndrome was made. The timing of raltegravir
initiation made it the most likely cause. Dermatologists
advised treatment with emollients, topical steroid and
prednisolone 30mg daily (a lower dose than usually used
for DRESS syndrome, to compensate for the PI interac-
tion). Raltegravir was stopped and PI recommenced.
Skin biopsy was consistent with a drug eruption. The
rash improved over the subsequent two weeks. The
patient continues on a reducing steroid regime. The
eosinophil count is declining.
Conclusions
This is the first report of a severe reaction to raltegravir.
DRESS syndrome is previously described in other anti
retrovirals [2] but not in relation to raltegravir. Clini-
cians should be aware of this potential adverse event.
Author details
1St Thomas’ Hospital, Harrison Wing, London, UK.
2St Thomas’ Hospital,
Dermatology, London, UK.
Published: 8 November 2010
References
1. Stellbrink HJ: Raltegravir in the management of HIV infected patients.
Drug Design Developement and Therapy 2008, 2:281-288.
2. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E: Adverse cutaneous
reactions associated with the newest antiretroviral drugs in patients
with human immunodeficiency virus infection. Journal of Antimicrobial
Chemotherapy 2008, 62:879-888.
doi:10.1186/1758-2652-13-S4-P110
Cite this article as: Perry et al.: Raltegravir-induced drug reaction with
eosinophilia and systemic symptoms (DRESS) syndrome: implications
for clinical practice and patient safety. Journal of the International AIDS
Society 2010 13(Suppl 4):P110.
1St Thomas’ Hospital, Harrison Wing, London, UK
Full list of author information is available at the end of the article
Perry et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P110
http://www.jiasociety.org/content/13/S4/P110
© 2010 Perry et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.